The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study

• Main Authors: D. J Ouyang (Author), Q. T Chen (Author), M. Anwar (Author), N. Xie (Author), Q. C. Ouyang (Author), P. Z. Fan (Author), L. Y. Qian (Author), G. N. Chen (Author), E. X. Zhou (Author), L. Guo (Author), X. W. Gu (Author), B. N. Ding (Author), X. H. Yang (Author), L. P. Liu (Author), C. Deng (Author), Z. Xiao (Author), J. Li (Author), Y. Q. Wang (Author), S. Zeng (Author), Shouman Wang (Author), Wenjun Yi (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited.Methods: Ninety-four patients who received pyrotinib as a thi...